GLP-1 drugs are being studied alongside established treatment for opioid use disorder. A small residential pilot reported less craving with liraglutide. The trial of oral semaglutide for alcohol use disorder measured different outcomes in a different condition, so its findings cannot answer whether GLP-1 drugs help with opioid use disorder.[1][2]
What the liraglutide pilot measured
The review of GLP-1 studies on smoking cessation examines a separate condition and different outcomes. A result for nicotine does not establish an effect on opioid use.
Penn State investigators reported preliminary results from a randomized, placebo-controlled study in residential treatment (n = 20). Participants recorded opioid cravings in real time. The investigators reported less craving with liraglutide. That small study cannot establish whether participants are more likely to avoid opioids, stay in treatment, or avoid an overdose over time.[1]
What the larger trials are designed to measure
The tirzepatide protocol plans to enroll about 310 adults who recently started buprenorphine. Its primary outcome is whether participants stay on buprenorphine at six months. A separate semaglutide protocol plans to enroll 200 outpatients on buprenorphine or methadone who continue to use nonprescribed opioids. Its primary outcome is abstinence from illicit or nonprescribed opioids during the study treatment period. Both protocols describe research that adds a GLP-1 drug to established care.[3][4]
What records can tell us about overdose
In a U.S. health-record study of 33,006 people with both type 2 diabetes and opioid use disorder, a semaglutide prescription was associated with fewer recorded opioid overdoses over one year than several other diabetes medications. Researchers matched participants on recorded characteristics, but the study did not randomly assign prescriptions. Unmeasured differences could influence the results.[5]